MP79-14 COMPLIANCE TO ORAL TREATMENT FOR PREMATURE EJACULATION – DATA FROM A SINGLE ACADEMIC CENTER

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP79-14 COMPLIANCE TO ORAL TREATMENT FOR PREMATURE EJACULATION – DATA FROM A SINGLE ACADEMIC CENTER Paolo Capogrosso, Edoardo Pozzi, Federico Belladelli, Giuseppe Fallara, Simone Cilio, Massimiliano Raffo, Fausto Negri, Ludovica Cella, Margherita Fantin, Alessandro Bertini, Luca Boeri, Christian Corsini, Francesco Lanzaro, Luigi Candela, Alessia D'Arma, Federico Dehò, Francesco Montorsi, and Andrea Salonia Paolo CapogrossoPaolo Capogrosso More articles by this author , Edoardo PozziEdoardo Pozzi More articles by this author , Federico BelladelliFederico Belladelli More articles by this author , Giuseppe FallaraGiuseppe Fallara More articles by this author , Simone CilioSimone Cilio More articles by this author , Massimiliano RaffoMassimiliano Raffo More articles by this author , Fausto NegriFausto Negri More articles by this author , Ludovica CellaLudovica Cella More articles by this author , Margherita FantinMargherita Fantin More articles by this author , Alessandro BertiniAlessandro Bertini More articles by this author , Luca BoeriLuca Boeri More articles by this author , Christian CorsiniChristian Corsini More articles by this author , Francesco LanzaroFrancesco Lanzaro More articles by this author , Luigi CandelaLuigi Candela More articles by this author , Alessia D'ArmaAlessia D'Arma More articles by this author , Federico DehòFederico Dehò More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , and Andrea SaloniaAndrea Salonia More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003356.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Oral therapy for premature ejaculation (PE) has been associated with high drop-out rates due to side effects and poor results. We compared patients compliance to dapoxetine prn vs. paroxetine OaD in men with PE in a real-life setting. METHODS: Data from 4105 patients with sexual dysfunctions prospectively collected at a single Sexual Medicine clinic in 2005-2022 were analysed. Overall, 342(8.3%) patients complained of PE and were treated either with dapoxetine 30-60mg prn or paroxetine 20mg OaD according to patients’ profile and preference. All completed the Premature Ejaculation Diagnostic Tool (PEDT) and the IIEF before and over the treatment course. Patients were re-assessed at 3 months from treatment start and thereafter every 6 months or as needed. Kaplan-Meier estimated treatment drop-out rates over time. Cox regression analysis assessed predictors of treatment discontinuation. RESULTS: Median (IQR) age was 47(36, 61) years. Median baseline PEDT score was 15 (10,17.5). Of all, 151(44%) and 191(56%) patients were treated with dapoxetine and paroxetine respectively. Patients receiving dapoxetine were younger (40(30,48) vs. 56(41,67); p<0.0001) and depicted worse baseline PEDT (16(14,18) vs. 8(3,14); p<0.0001) as compared with those receiving paroxetine. Overall, 329(96%) discontinued the drugs at some point throughout the treatment course, showing only a slight mean improvement of PEDT from baseline of -0.4(95%CI:-0.8,1.7) and -0.8(95%CI:-0.7,1.3) with dapoxetine and paroxetine, respectively. At Kaplan-Meier (Figure 1) the two groups did not differ in terms of treatment dropout over time (p=0.3), with estimated discontinuation rates of 27%(15,45) and 55%(37,75) at 12 and 24 months for dapoxetine and 13%(7,24) and 47%(32,65) for paroxetine. Younger patients were at higher risk of treatment drop-out (HR:0.95, 95%CI:0.91,0.99; p=0.03) after accounting for PEDT, IIEF-EF and type of treatment. CONCLUSIONS: PE still represents a therapeutic challenge with high treatment drop-out rates and only minor improvements. Younger patients appear at higher risk of oral therapies discontinuation and maybe better candidates for a multimodal treatment. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1146 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Paolo Capogrosso More articles by this author Edoardo Pozzi More articles by this author Federico Belladelli More articles by this author Giuseppe Fallara More articles by this author Simone Cilio More articles by this author Massimiliano Raffo More articles by this author Fausto Negri More articles by this author Ludovica Cella More articles by this author Margherita Fantin More articles by this author Alessandro Bertini More articles by this author Luca Boeri More articles by this author Christian Corsini More articles by this author Francesco Lanzaro More articles by this author Luigi Candela More articles by this author Alessia D'Arma More articles by this author Federico Dehò More articles by this author Francesco Montorsi More articles by this author Andrea Salonia More articles by this author Expand All Advertisement PDF downloadLoading ...